Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Jw Cayman Therapeutics Co Ltd
JWCTFJW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China. Address: Building B, Shanghai, China
Analytics
WallStreetin tavoitehinta
23.17 HKDP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut JWCTF
Osinkoanalytiikka JWCTF
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria JWCTF
Osakkeen arvostus JWCTF
Talousasiat JWCTF
Tuloksia | 2019 | Dynamiikka |